Growth Metrics

Cumberland Pharmaceuticals (CPIX) Liabilities and Shareholders Equity (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $76.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 1.64% to $76.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $280.6 million through Dec 2025, down 10.18% year-over-year, with the annual reading at $76.8 million for FY2025, 1.64% up from the prior year.
  • Liabilities and Shareholders Equity hit $76.8 million in Q4 2025 for Cumberland Pharmaceuticals, up from $65.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $96.7 million in Q1 2022 to a low of $65.9 million in Q3 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $83.4 million across 5 years, with a median of $86.0 million in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: grew 10.02% in 2022 and later fell 14.2% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $84.5 million in 2021, then increased by 10.02% to $92.9 million in 2022, then dropped by 12.0% to $81.8 million in 2023, then decreased by 7.57% to $75.6 million in 2024, then rose by 1.64% to $76.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CPIX at $76.8 million in Q4 2025, $65.9 million in Q3 2025, and $67.9 million in Q2 2025.